Available data give a high suspicion for the association of Zika virus with development of neurological disorders, including congenital microcephaly and Guillain-Barré syndrome. 2 As such, pregnant women are considered a high-risk population. Few studies to date suggest causality; however, observational data associate small fetal head size and brain calcifications with Zika infection. Between October 2015 and January 2016, in Brazil alone, about 4000 babies were born with microcephaly, which represents a 20-fold increase from the number of cases occurring between 2010 and 2014. 5 Effective prevention strategies are key to control of virus transmission and spread. These strategies can be divided into 2 broad categories: those affecting mosquito population control and those targeting individuals. Focusing efforts to control mosquito populations in endemic regions should be a priority; however, vector-control strategies employed to control dengue and chikungunya viruses within affected regions have failed in the past. 6 Efforts must be coordinated to effectively reduce the burden of carrier mosquitos and subsequently the rates of transmission to humans. Unfortunately, no vaccine to prevent Zika transmission is available, nor will any be available in the near future.
Tourists and those living within endemic regions should take precautions against mosquito bites. Currently, the US Centers for Disease Control and Prevention (CDC) recommends use of mosquito repellent containing N,N-diethyl-3-meta-toluamide (DEET), picaridin, oil of lemon eucalyptus, or IR3535. 7 One study showed that products with DEET were most effective for the longest duration. 8 Recommendations also include wearing clothing that covers the arms and legs and/or using permethrin-treated clothing. 7 Additional measures may include using insecticide-treated mosquito nets when sleeping and minimizing time in areas of high mosquito volume. Postponement of travel plans to Zika-active areas can also be considered.
The advent of sexual transmission prompted the CDC to release interim guidelines for prevention in early 2016. 9 These guidelines are very important from a public health perspective, as the virus may persist longer in semen than in blood. 10 The CDC advises men who reside in or have travelled to a Zika-active area and whose partners are pregnant to abstain from sexual activity or to use condoms consistently and correctly during oral, vaginal, and anal intercourse. For men who reside in or have travelled to a Zika-active area and whose partners are not pregnant, it is advised that they consider abstaining from sexual activity or using condoms consistently and correctly during sex. 9 As "informed tourists" in Brazil, we observed attempts at raising awareness through media and in public spaces (Figure 1) . However, information about the potential seriousness of the infection and appropriate prevention strategies was not readily available. Specifically, mosquito repellent was not easy to find and, once located (inside a community pharmacy), products were limited in terms of both number and selection. Therefore, we urge health professionals encountering patients who are planning to visit Zikaactive areas to educate the travellers about the disease and to encourage them to purchase repellents and other prevention products and clothing before travel. Pharmacists must also be diligent in questioning returning patients about potential exposure to the Zika virus and must learn to recognize signs and symptoms consistent with infection.
Despite best efforts to prevent Zika virus disease at an individual patient level, a coordinated global strategy for virus control is urgently needed. Such a strategy is especially important as Brazil prepares to host the 2016 Summer Olympic Games and as travel to active zones increases in the coming months.
Both studies employed a validated, stability-indicating assay. Thus, we hypothesize that the reason for the discordant results involves the underlying methodology of experimental sampling times. Walker and others 1 sampled and observed concentrations of ertapenem at 24-h intervals. As a result, they were required to use statistical interpolation to determine the point at which ertapenem concentration dropped below 90% of baseline and were forced to assume zero-order degradation over the initial 24 h. This approach contradicts the earliest studies of ertapenem, which showed that stability was concentration-dependent, with higher concentrations having a more rapid degradation rate than lower concentrations. 3, 4 In contrast, our study design involved sampling every hour during the first 24 h, as we anticipated that degradation of a highconcentration solution would be more rapid than currently reported for standard ertapenem concentrations (10 and 20 mg/mL), for which the period of stability is 6 h. 5, 6 In room temperature studies, we observed mean ertapenem concentrations below 90% at 1 h, and our use of interpolation was over only a short time interval. Essentially, Walker and others 1 calculated the beyond-use date as 5.5 h, whereas in our study, we actually measured and observed it at less than 1 h. Prescribing information for both the United States and Canada reports the room temperature stability of ertapenem 1000 mg once diluted in 50 mL of 0.9% sodium chloride for treatment of infection (i.e., to a final concentration of 20 mg/mL) as being no longer than 6 h. 5, 6 Therefore, it would not be consistent for a solution with 5-fold greater concentration to have the same room temperature stability. Additionally, the prescribing information recommends that the formulation containing 1000 mg in 3.2 mL of 1% lidocaine hydrochloric acid used for intramuscular injection (i.e., a final concentration of 312.5 mg/mL) should be administered within 1 h. Although it involves a different diluent, this recommendation is more in line with our observations.
